Filing Analysis
Galectin Therapeutics Inc. issued an 8-K to announce its results of operations and financial condition for the six months ended June 30, 2026, alongside a business update.
🚩 Red Flags
- No specific financial losses or cash burn figures are provided in the text of this 8-K; actual severity depends on the referenced Exhibit 99.1.
📋 Key Facts
- Reporting period: Six months ended June 30, 2026.
- Filing date: August 14, 2026.
- The filing incorporates by reference a press release dated August 14, 2026 (Exhibit 99.1).
- Information under Item 2.02 is furnished, not filed.
Galectin Therapeutics Inc. issued an 8-K to announce the results of a recent Type C meeting held with the U.S. Food and Drug Administration (FDA). The specific details of the meeting outcomes are contained in an attached press release.
📋 Key Facts
- The company held a Type C meeting with the FDA regarding its clinical programs.
- The filing was made on June 23, 2026.
- Information is furnished under Item 7.01 (Regulation FD Disclosure) and not filed for purposes of Section 18 liability.
Galectin Therapeutics Inc. reported its financial results for the first quarter ended March 31, 2026, and provided a general business update. The results were announced via a press release furnished as an exhibit to the filing.
📋 Key Facts
- Announced Q1 2026 financial results for the period ending March 31, 2026.
- Provided a business update alongside financial results.
- Information furnished under Item 2.02 (Results of Operations and Financial Condition).
- Press release included as Exhibit 99.1.
Galectin Therapeutics Inc. reported its financial results for the fiscal year ended December 31, 2025, and provided a business update via a press release on March 31, 2026.
📋 Key Facts
- The filing reports financial results for the full year ended December 31, 2025.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- Jack W. Callicutt, Chief Financial Officer, signed the report on March 31, 2026.
- The company incorporated by reference a press release (Exhibit 99.1) containing the detailed financial data.
Galectin Therapeutics Inc. appointed Dr. Henry Brem, a renowned neurosurgeon and translational medicine expert from Johns Hopkins University, to its Board of Directors effective March 12, 2026. Dr. Brem brings extensive experience in drug delivery systems and clinical research, having previously served as the Neurosurgeon-in-Chief at Johns Hopkins.
📋 Key Facts
- Dr. Henry Brem was appointed to the Board of Directors on March 12, 2026.
- Dr. Brem served as Director of the Department of Neurosurgery at Johns Hopkins from 2000 until 2025.
- He is credited with developing Gliadel® wafers for brain tumors and has published over 416 peer-reviewed papers.
- Dr. Brem will receive standard non-employee director compensation as per the company's existing program.
- There are no reported related-party transactions or arrangements involving Dr. Brem.
Galectin Therapeutics Inc. announced the approval of cash retention bonuses for its Chief Medical Officer and Chief Financial Officer, effective January 16, 2026.
🚩 Red Flags
- Retention bonuses often signal management instability or high turnover risk in micro-cap biotech firms.
- The use of cash for retention rather than equity may indicate a desire to avoid further dilution but also highlights immediate liquidity usage.
📋 Key Facts
- Dr. Khurram Jamil (CMO) granted a $300,000 cash retention bonus.
- Jack Callicutt (CFO) granted a $150,000 cash retention bonus.
- Bonuses to be paid in three equal installments on June 1, Sept 1, and Dec 1, 2026.
- Clawback provision: Bonuses must be repaid if officers resign without good reason or are terminated for cause before December 31, 2026.
Galectin Therapeutics, Inc. announced the resignation of Marc Rubin from its Board of Directors effective January 10, 2026. The company explicitly stated that the resignation was not due to any disagreements regarding operations, policies, or practices.
📋 Key Facts
- Marc Rubin resigned from the Board of Directors on January 10, 2026.
- The resignation is not related to any disagreement with the Company's operations, policies, or practices.
Galectin Therapeutics entered into a $10 million supplemental line of credit agreement with Richard E. Uihlein, an individual lender. The financing involves convertible promissory notes and warrants that include significant dilution potential for existing shareholders.
🚩 Red Flags
- Related-party transaction (financing from an individual lender rather than a traditional institutional bank)
- Significant potential dilution via convertible promissory notes and warrants
- Warrant exercise price set at a 50% premium to current market price, but with a floor tied to the current date's closing price
- Unsecured debt structure increases risk profile for existing equity holders
📋 Key Facts
- Lender: Richard E. Uihlein
- Total Line of Credit: Up to $10.00 million
- Interest Rate: Applicable Federal Rate (3.60%) + 2% premium
- Maturity Date: June 30, 2027
- Warrants: Up to 400,000 total shares (200,000 immediate; 200,000 upon borrowing) with exercise price at 150% of closing price (floor at Dec 19, 2025 price)
- Conversion Feature: Lender has the option to convert principal and interest into common stock
- Registration Rights: Company must register shares within 180 days of conversion or exercise
Galectin Therapeutics Inc. reported the results of its 2025 Annual Meeting of Stockholders held on December 3, 2025. The meeting included the election of directors, advisory votes on executive compensation, and the ratification of the company's independent auditor.
📋 Key Facts
- Annual Meeting held on December 3, 2025.
- All eleven nominated directors were elected to serve until the next annual meeting or their successors.
- Stockholders approved a non-binding advisory resolution regarding executive compensation (25,260,489 votes for).
- The Board determined that shareholder advisory votes on executive compensation will occur every three years based on voting results.
- Cherry Bekaert LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
Galectin Therapeutics Inc. filed an 8-K to provide a transcript of a presentation made following its Annual Meeting of Stockholders on December 3, 2025.
📋 Key Facts
- The filing is pursuant to Item 7.01 (Regulation FD Disclosure).
- A transcript of the presentation from the Annual Meeting of Stockholders is attached as Exhibit 99.1.
- The information provided under Item 7.01 is furnished but not 'filed' for purposes of Section 18 of the Exchange Act.
Galectin Therapeutics Inc. issued an 8-K to announce its results of operations and financial condition for the nine months ended September 30, 2025, alongside a business update.
📋 Key Facts
- Reporting period: Nine months ended September 30, 2025.
- Filing date: November 14, 2025.
- The filing incorporates by reference a press release dated November 14, 2025 (Exhibit 99.1).
- Information under Item 2.02 is furnished, not filed.
Galectin Therapeutics Inc. issued an 8-K to announce the presentation of its NAVIGATE trial results at the AASLD 2025 Annual Meeting and provided an updated corporate presentation.
📋 Key Facts
- Presented NAVIGATE trial results at the American Association for the Study of Liver Diseases (AASLD) 2025 Annual Meeting on November 10, 2025.
- Released an updated Corporate Presentation via Exhibit 99.2.
- The information was furnished under Item 7.01 (Regulation FD Disclosure) and is not considered 'filed' for liability purposes.
Galectin Therapeutics Inc. has updated its corporate presentation as part of a Regulation FD disclosure. This is a routine informational update typically used to communicate company strategy or clinical progress to the public.
📋 Key Facts
- Company posted an updated Corporate Presentation to its website on September 8, 2025.
- The information is furnished under Item 7.01 (Regulation FD Disclosure) and is not considered 'filed' for purposes of Section 18 liability.
- The filing includes Exhibit 99.1 containing the updated presentation.
Galectin Therapeutics Inc. issued an 8-K to announce its results of operations and financial condition for the six months ended June 30, 2025, alongside a business update.
📋 Key Facts
- Report date: August 14, 2025
- Reporting period: Six months ended June 30, 2025
- The filing incorporates by reference a press release dated August 14, 2025 (Exhibit 99.1)
- Information under Item 2.02 is furnished, not filed.
Galectin Therapeutics entered into a $10 million supplemental line of credit agreement with Richard E. Uihlein, involving convertible promissory notes and warrants. The filing also details significant cash retention bonuses for the CFO and CMO aimed at ensuring stability through year-end.
🚩 Red Flags
- Convertible debt with a floor price ($3.00) often leads to significant dilution for existing shareholders.
- Warrant exercise prices set at 150% of the closing price indicate high cost of capital.
- Retention bonuses for key officers (CFO/CMO) suggest management is prioritizing stability amidst potential liquidity or operational uncertainty.
- Contingent employee bonuses tied to a specific partnership agreement by Dec 31, 2025, suggests heavy reliance on a single milestone for cash flow/stability.
📋 Key Facts
- Entered into July 2025 Supplemental Line of Credit Agreement with Lender Richard E. Uihlein on July 8, 2025.
- Line of credit amount: up to $10.00 million for working capital needs.
- Credit availability through April 30, 2026; notes due on or before September 30, 2026.
- Interest rate: Applicable Federal Rate (4.05%) + 2% (total ~6.05%).
- Conversion feature: Lender can convert principal/interest into common stock at a floor price of $3.00 per share.
- Warrants issued to Lender for up to 200,000 shares initially, plus an additional 200,000 shares ratably upon borrowings; exercise price between $3.00 and $10.00 (150% of closing price).
- Company must register issued shares with the SEC within 180 days of conversion or exercise.
- Approved $100,000 cash retention bonuses for CMO Dr. Khurram Jamil and CFO Jack Callicutt, payable by July 15, 2025.
Galectin Therapeutics Inc. filed an 8-K to furnish a corporate presentation regarding Belapectin for MASH Cirrhosis and Portal Hypertension under Regulation FD. The filing includes information shared via a webcast scheduled for June 16, 2025.
📋 Key Facts
- Company posted a presentation titled 'Belapectin for MASH Cirrhosis and Portal Hypertension' to its website on June 16, 2025.
- A webcast discussing the presentation was scheduled for June 16, 2025, at 12:00 p.m. ET.
- The information is furnished under Item 7.01 and is not considered 'filed' for purposes of Section 18 liability.
Galectin Therapeutics Inc. issued an 8-K to announce its results of operations and financial condition for the three months ended March 31, 2025, alongside a business update.
📋 Key Facts
- Reporting period: Three months ended March 31, 2025
- Filing date: May 15, 2025
- The filing incorporates a press release via Exhibit 99.1 containing financial results and business updates.
Galectin Therapeutics Inc. has released an updated corporate presentation and a corresponding press release to be used for investor relations, conferences, and analyst meetings.
📋 Key Facts
- Company issued an updated corporate presentation on May 12, 2025 (Exhibit 99.1).
- The filing includes a press release dated May 12, 2025 (Exhibit 99.2).
- Information is furnished under Item 7.01 (Regulation FD Disclosure) and not filed for purposes of Section 18 liability.
Galectin Therapeutics Inc. issued an 8-K to announce its year-end financial results for the period ending December 31, 2024, and provided a general business update via press release.
📋 Key Facts
- Report date: March 31, 2025
- Reporting Period: Year ended December 31, 2024
- The filing incorporates by reference a press release dated March 31, 2025 (Exhibit 99.1)
- Information under Item 2.02 is furnished, not filed.
Galectin Therapeutics Inc. has released an updated corporate presentation to be used for investor relations, conferences, and analyst meetings.
📋 Key Facts
- The company updated its corporate presentation on March 5, 2025.
- The presentation is intended for use in meetings with investors, shareholders, and analysts.
- Information provided under Item 7.01 is considered 'furnished' rather than 'filed', limiting liability under Section 18 of the Exchange Act.
Galectin Therapeutics Inc. filed an 8-K to announce the issuance of a press release on February 18, 2025. The filing does not contain specific material financial or structural changes within the body of the text itself.
📋 Key Facts
- The company issued a press release dated February 18, 2025 (Exhibit 99.1).
- The filing is an Item 8.01 'Other Items' disclosure.
Galectin Therapeutics Inc. reported the results of its 2024 Annual Meeting of Stockholders held on January 23, 2025. The meeting included the election of the full slate of directors and the ratification of Cherry Bekaert LLP as the independent auditor for the fiscal year ending December 31, 2024.
📋 Key Facts
- Annual Meeting held on January 23, 2025.
- All nominated directors were elected to serve until the next annual meeting or their successors.
- Cherry Bekaert LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2024.
- Total votes cast for auditor ratification: 38,723,588 in favor.
Galectin Therapeutics Inc. filed an 8-K to provide a transcript of a presentation made following its Annual Meeting of Stockholders on January 23, 2025.
📋 Key Facts
- The filing is pursuant to Item 7.01 (Regulation FD Disclosure).
- A transcript of the company's presentation from the Annual Meeting of Stockholders was attached as Exhibit 99.1.
- The event occurred on January 23, 2025.
Galectin Therapeutics Inc. has released an updated corporate presentation via Item 7.01 (Regulation FD Disclosure) to be used for investor and analyst meetings.
📋 Key Facts
- The company updated its corporate presentation on January 13, 2025.
- The presentation is intended for use at conferences and meetings with investors, shareholders, and analysts.
- Information provided under Item 7.01 is 'furnished' rather than 'filed', meaning it is not subject to the same liability standards as filed information.
Galectin Therapeutics Inc. filed an 8-K to announce a press release issued on December 20, 2024. The filing does not contain specific financial data or material event details within the text itself, referring instead to Exhibit 99.1.
📋 Key Facts
- Filing date: December 20, 2024
- The company issued a press release (Exhibit 99.1) as the primary content of this report.
- Filed under Item 8.01 (Other Items).
Galectin Therapeutics Inc. has released an updated corporate presentation to be used for investor relations and conference meetings. The filing is a standard Regulation FD disclosure intended to provide current information to the public.
📋 Key Facts
- Company updated its corporate presentation on November 14, 2024.
- The presentation will be used at conferences and meetings with investors, shareholders, and analysts.
- Information is furnished under Item 7.01 (Regulation FD Disclosure) and is not considered 'filed' for liability purposes.
Galectin Therapeutics Inc. filed an 8-K to announce its quarterly results of operations and financial condition for the three months ended September 30, 2024, alongside a business update.
📋 Key Facts
- Report date: November 14, 2024
- Reporting period: Three months ended September 30, 2024
- The filing incorporates by reference a press release dated November 14, 2024 (Exhibit 99.1)
- Information under Item 2.02 is furnished, not filed.
Galectin Therapeutics Inc. has released an updated corporate presentation to be used for investor relations, conferences, and analyst meetings.
📋 Key Facts
- The company updated its corporate presentation on September 9, 2024.
- The presentation is intended for use in investor/shareholder communications and at industry conferences.
- Information provided under Item 7.01 is considered 'furnished' rather than 'filed', limiting liability under Section 18 of the Exchange Act.
Galectin Therapeutics Inc. issued an 8-K to announce its results of operations and financial condition for the three months ended June 30, 2024, alongside a business update.
📋 Key Facts
- Report covers the three months ended June 30, 2024.
- The filing incorporates by reference a press release dated August 13, 2024.
- Information under Item 2.02 is furnished, not filed.
Galectin Therapeutics Inc. announced a leadership transition in its medical department, promoting Dr. Khurram Jamil to Chief Medical Officer effective August 1, 2024, following the resignation of Dr. Pol Boudes.
🚩 Red Flags
- Departure of a C-suite officer (CMO) can sometimes signal internal friction or strategic shifts, though no cause was cited here.
📋 Key Facts
- Dr. Khurram Jamil promoted from VP, Clinical Development to Chief Medical Officer (CMO) effective August 1, 2024.
- Dr. Jamil's compensation includes a $500,000 annual base salary and a target bonus of up to 30%.
- Equity compensation for Dr. Jamil includes 10,000 restricted stock award shares and options to purchase 100,000 common shares.
- Dr. Pol Boudes resigned as CMO on July 26, 2024; his last day is August 1, 2024.
- Dr. Jamil previously served at Mallinckrodt Pharmaceuticals and holds board certification in General Surgery.
Galectin Therapeutics Inc. issued an 8-K to announce its quarterly results of operations and financial condition for the three months ended March 31, 2024, alongside a business update.
📋 Key Facts
- Reporting period: Three months ended March 31, 2024
- Filing date: May 15, 2024
- The filing incorporates by reference a press release dated May 15, 2024 (Exhibit 99.1)
- Information under Item 2.02 is furnished, not filed.
Galectin Therapeutics Inc. filed an 8-K to announce its year-end financial results for the period ending December 31, 2023, and provided a general business update via press release.
📋 Key Facts
- Report date: March 29, 2024
- Reporting period: Fiscal year ended December 31, 2023
- The filing incorporates by reference a press release issued on March 29, 2024
- Information under Item 2.02 is furnished, not filed